Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496002 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus
A Phase 3 study, sponsored by Pharmasset.
- Terminated
- Registry status
- Phase 3
- Development phase
NCT00496002: Clinical Trial Phase 3 study, sponsored by Pharmasset.
NCT00496002 is a Phase 3 study that was terminated before completion, run by Pharmasset. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00496002, a Phase 3 study, was terminated before completion, sponsored by Pharmasset.
- TERMINATED
- Registry status
- Phase 3
- Development phase
Study Summary
The objectives of this study are to compare in nucleoside treatment-naïve subjects, the efficacy and safety of clevudine 30 mg once daily versus adefovir 10 mg once daily, each as monotherapy, for 48 weeks and 96 weeks.
Interventions
- DRUG Adefovir
- DRUG Clevudine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2007-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00496002
The ClinicalTrials.gov registry entry for NCT00496002 describes a study currently listed as terminated, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Pharmasset, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Adefovir is the first listed.
NCT00496002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00496002 about?
NCT00496002 is a clinical study titled "Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus". The objectives of this study are to compare in nucleoside treatment-naïve subjects, the efficacy and safety of clevudine 30 mg once daily versus adefovir 10 mg once daily, each as monotherapy, for 48 weeks and 96 weeks.
What is the current status of trial NCT00496002?
This trial is currently terminated. It is a Phase 3 study. The study started on 2007-08.
What interventions are being tested in trial NCT00496002?
The interventions under investigation include: Adefovir (DRUG), Clevudine (DRUG).
Who is sponsoring clinical trial NCT00496002?
This trial is sponsored by Pharmasset, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.